### Abstract

The study of the magnitude and variation of drug response is defined as pharmacodynamics (PDs). PD models examine plasma concentration and effect relationship. It can predict the archetypal effect ([Formula: see text]) of a drug as a function of the drug concentration ([Formula: see text]) and estimate an unknown PD parameter ([Formula: see text]). The PD models have been described as fixed, linear, log-linear, [Formula: see text], sigmoid [Formula: see text], and indirect PD response. Ligand binding model is an example of a PD model that works on the underpinning PD principle of a drug, eliciting its pharmacological effect at the receptor site. The pharmacological effect is produced by the drug binding to the receptor to either activate or antagonise the receptor. Ligand binding models describe a system of interacting components, i.e. the interaction of one or more ligands with one or more binding sites. The [Formula: see text] model is the central method that provides an empirical justification for the concentration/dose-effect relationship. However, for ligand binding models justification is provided by theory of receptor occupancy. In essence, for ligand binding models, the term [Formula: see text] is best used to describe the fraction of receptors occupied at a particular ligand concentration. It is stated that the [Formula: see text], which means the effect of a drug should depend on the fraction of receptors that are occupied. In the future, network-based systems pharmacology models using ligand binding principles could be an effective way of understanding drug-related adverse effects. This will facilitate and strengthen the development of rational drug therapy in clinical practice.

Original language | English |
---|---|

Pages (from-to) | 165-175 |

Number of pages | 11 |

Journal | Saudi Pharmaceutical Journal |

Volume | 25 |

Issue number | 2 |

Early online date | 9 Jul 2016 |

DOIs | |

Publication status | Published - 1 Feb 2017 |

### Fingerprint

### Keywords

- Competitive binding
- E model
- Fractional occupancy
- Ligand binding
- Pharmacodynamic model
- Pharmacodynamics
- Receptor

### ASJC Scopus subject areas

- Pharmacology
- Pharmaceutical Science

### Cite this

**An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice.** / Salahudeen, Mohammed Saji; Nishtala, Prasad S.

Research output: Contribution to journal › Review article

*Saudi Pharmaceutical Journal*, vol. 25, no. 2, pp. 165-175. https://doi.org/10.1016/j.jsps.2016.07.002, https://doi.org/10.1016/j.jsps.2016.07.002

}

TY - JOUR

T1 - An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice

AU - Salahudeen, Mohammed Saji

AU - Nishtala, Prasad S.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The study of the magnitude and variation of drug response is defined as pharmacodynamics (PDs). PD models examine plasma concentration and effect relationship. It can predict the archetypal effect ([Formula: see text]) of a drug as a function of the drug concentration ([Formula: see text]) and estimate an unknown PD parameter ([Formula: see text]). The PD models have been described as fixed, linear, log-linear, [Formula: see text], sigmoid [Formula: see text], and indirect PD response. Ligand binding model is an example of a PD model that works on the underpinning PD principle of a drug, eliciting its pharmacological effect at the receptor site. The pharmacological effect is produced by the drug binding to the receptor to either activate or antagonise the receptor. Ligand binding models describe a system of interacting components, i.e. the interaction of one or more ligands with one or more binding sites. The [Formula: see text] model is the central method that provides an empirical justification for the concentration/dose-effect relationship. However, for ligand binding models justification is provided by theory of receptor occupancy. In essence, for ligand binding models, the term [Formula: see text] is best used to describe the fraction of receptors occupied at a particular ligand concentration. It is stated that the [Formula: see text], which means the effect of a drug should depend on the fraction of receptors that are occupied. In the future, network-based systems pharmacology models using ligand binding principles could be an effective way of understanding drug-related adverse effects. This will facilitate and strengthen the development of rational drug therapy in clinical practice.

AB - The study of the magnitude and variation of drug response is defined as pharmacodynamics (PDs). PD models examine plasma concentration and effect relationship. It can predict the archetypal effect ([Formula: see text]) of a drug as a function of the drug concentration ([Formula: see text]) and estimate an unknown PD parameter ([Formula: see text]). The PD models have been described as fixed, linear, log-linear, [Formula: see text], sigmoid [Formula: see text], and indirect PD response. Ligand binding model is an example of a PD model that works on the underpinning PD principle of a drug, eliciting its pharmacological effect at the receptor site. The pharmacological effect is produced by the drug binding to the receptor to either activate or antagonise the receptor. Ligand binding models describe a system of interacting components, i.e. the interaction of one or more ligands with one or more binding sites. The [Formula: see text] model is the central method that provides an empirical justification for the concentration/dose-effect relationship. However, for ligand binding models justification is provided by theory of receptor occupancy. In essence, for ligand binding models, the term [Formula: see text] is best used to describe the fraction of receptors occupied at a particular ligand concentration. It is stated that the [Formula: see text], which means the effect of a drug should depend on the fraction of receptors that are occupied. In the future, network-based systems pharmacology models using ligand binding principles could be an effective way of understanding drug-related adverse effects. This will facilitate and strengthen the development of rational drug therapy in clinical practice.

KW - Competitive binding

KW - E model

KW - Fractional occupancy

KW - Ligand binding

KW - Pharmacodynamic model

KW - Pharmacodynamics

KW - Receptor

UR - http://www.scopus.com/inward/record.url?scp=84997216970&partnerID=8YFLogxK

U2 - 10.1016/j.jsps.2016.07.002

DO - 10.1016/j.jsps.2016.07.002

M3 - Review article

VL - 25

SP - 165

EP - 175

JO - Saudi Pharmaceutical Journal

JF - Saudi Pharmaceutical Journal

SN - 1319-0164

IS - 2

ER -